PMVP advances toward NDA filing with Phase 2 data, Orphan designation; cash to Q2 2027

Filed May 12, 2026 · Period ending March 31, 2026 · Compared to 10-Q May 9, 2025 · ~1 min read

Key Changes

• high

  Company plans to file New Drug Application in Q1 2027 for rezatapopt in platinum-resistant ovarian cancer with TP53 Y220C mutation, following interim Phase 2 data announced September 2025.

  MD&A: NDA filing timeline verify on EDGAR →
• high

  FDA granted Orphan Drug Designation in March 2026 for rezatapopt in ovarian, fallopian tube, and primary peritoneal cancers, providing seven years market exclusivity upon approval and potential tax credits.

  MD&A: Orphan Drug Designation verify on EDGAR →
• high

  Cash runway shortened to Q2 2027 (15 months) from prior projection of "at least through end of 2026" (9+ months), with cash declining from $165.8M to $93.5M year-over-year.

  MD&A: Cash runway projection verify on EDGAR →